查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2037547

生物製藥市場預測－全球分析（按產品類型、藥物分類、給藥途徑、生產模式、治療應用、最終用戶和地區分類）——2034年

Biopharmaceuticals Market Forecasts to 2034 - Global Analysis By Product Type, Drug Classification, Route of Administration, Manufacturing Model, Therapeutic Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

全球生物製藥市場預計到 2026 年將達到 6,070 億美元，並在預測期內以 10.3% 的複合年成長率成長，到 2034 年達到 1.33 兆美元。

生物製藥是指利用生物技術生產的藥物，包括源自活體生物的治療性蛋白質、單株抗體、疫苗和基因療法。這些先進治療方法以前所未有的精準度靶向特定疾病機制，徹底改變了醫療保健，尤其是在腫瘤學、自體免疫疾病和罕見遺傳疾病領域。市場既包括專利原創生物製藥，也包括專利到期後提供價格更實惠的替代療法的生物相似藥，從而在全球醫療保健系統中營造出一個充滿活力、兼顧創新、可及性和法律規範的局面。

慢性病和自體免疫疾病盛行率增加

全球癌症、類風濕性關節炎、糖尿病和多發性硬化症等疾病的日益增多，正推動著對生物製藥解決方案前所未有的需求。與傳統的小分子藥物不同，生物製藥具有標靶作用機制，能夠作用於疾病的潛在通路，通常在傳統治療方法無效時提供有效的治療方案。已開發國家人口老化以及新興經濟體文明病的負擔，進一步加劇了這種需求。醫療衛生系統日益重視使用生物製藥治療慢性疾病，並認知到其在改善患者預後和降低長期住院成本方面的潛力。這種持續的臨床需求，為所有治療領域的市場持續擴張奠定了堅實的基礎。

高昂的製造和開發成本

生物製藥生產的複雜性造成了巨大的財務壁壘，限制了市場准入並阻礙了創新。與化學合成藥物不同，生物製藥需要活細胞培養、嚴格的無菌環境和先進的純化工藝，生產設施的建設和驗證成本高達數億美元。加上長達十多年的研發週期和昂貴的臨床試驗，一種生物製藥的上市成本可能超過20億美元。這些成本推高了治療費用，加重了醫療預算的負擔，並限制了病患的用藥機會。在開發中國家，由於生物製藥覆蓋範圍不足，這種影響尤其顯著。

專利到期導致生物相似藥市場擴張

重磅生物製藥專利到期為生物相似藥的研發和市場准入帶來了前所未有的機會。與學名藥不同，生物相似藥需要進行大量的分析和臨床試驗才能證明其與原廠藥的等效性，但它們可以節省20%至30%的成本，並顯著改善患者的用藥可及性。隨著治療自體免疫疾病、癌症和糖尿病的主要生物製藥的專利在預測期內陸續到期，一個價值數十億美元的市場正在向生物相似藥生產商敞開大門。美國、歐洲和新興市場的法律規範已經成熟，核准流程也更加清晰。這些生物相似藥的陸續上市有望改變我們治療患者的方式，同時為研發公司創造巨大的商機。

免疫抗原性和安全性問題

這些療法的生物學特性存在引發不良免疫反應的風險，威脅病人安全和監管核准。免疫抗原性是指患者的免疫系統將生物製藥識別為外來物質並產生抗藥性抗體的現象，這些抗體可能中和治療效果、改變藥物動力學或引發嚴重的過敏反應，包括過敏性休克。即使生產過程的微小變化也可能改變產品的免疫抗原性原性，因此核准後需要密切監測。一些備受矚目的安全事件導致產品召回和監管審查力度加大，增加了研發過程中的不確定性。這些問題對於生物相似藥尤其重要，因為即使與參考產品有細微差異，也可能引發意想不到的免疫反應，這可能會阻礙醫生和患者的接受度。

新冠疫情的影響：

新冠疫情對生物製藥市場產生了複雜的影響，在擾亂各個細分領域的同時，也加速了其發展。封鎖措施和醫療資源的重新分配延緩了非新冠生物生物製藥候選藥物的臨床試驗，同時也擾亂了原料供應鏈。然而，疫情極大地加速了疫苗研發平台的建設，並展現了創新生物製藥方法的有效性，其中mRNA技術以創紀錄的速度獲得了監管部門的核准。住院人數的激增使醫療系統不堪重負，暫時減少了針對慢性疾病的特定生技藥品療法的啟動。疫情也凸顯了國內生物製造能力的戰略重要性，並促使政府進行投資和政策調整，最終將惠及整個生物製藥產業。

在預測期內，創新生物製劑領域預計將佔據最大的市場佔有率。

在強大的專利保護和持續不斷的新型生物製劑研發管線的支持下，創新生物製劑領域預計將在預測期內佔據最大的市場佔有率。製藥公司正大力投資研發，以發現能夠滿足未被滿足的醫療需求的First-in-Class單株抗體、融合蛋白和基因治療方法。這些創新產品定價可能很高，並且在獲得監管部門核准後享有長達12年的市場獨佔期。光是腫瘤領域，就湧現出許多年銷售額超過50億美元的重磅創新生物製劑。強大的智慧財產權體系和針對孤兒藥研發的監管激勵措施預計將使創新生物製劑在整個預測期內保持其市場主導地位。

在預測期內，口服給藥領域預計將呈現最高的複合年成長率。

在預測期內，口服給藥領域預計將呈現最高的成長率。這反映了非注射途徑生物製藥遞送技術的顯著進步。傳統的生物製藥由於在胃腸道內分解而需要注射，但諸如滲透增強劑、酶抑製劑和先進的包封技術等新型製劑技術使得肽類和小分子蛋白的口服給藥成為可能。患者更傾向於口服給藥而非注射，這有助於提高需要長期治療的慢性病患者的治療依從性。一些針對糖尿病和類風濕性關節炎等疾病的口服胜肽製劑近期已獲得監管部門核准，還有更多製劑正處於後期研發階段。這種變革性的轉變有望顯著提高生物製藥的可及性和便利性。

市佔率最大的地區：

在整個預測期內，北美預計將佔據最大的市場佔有率，這得益於其成熟的生物技術生態系統、充足的研發資金和有利的醫療保險政策。僅美國就佔全球醫藥品研究開發費用的近一半，並且是大多數領先創新者的所在地。該地區的法規結構，包括《生技藥品價格競爭與創新法案》，為創新藥物和生物相似藥提供了清晰的核准流程。強而有力的智慧財產權保護鼓勵持續投資，而廣泛的公共和私人保險覆蓋範圍則確保了患者能夠獲得昂貴的生物製藥。這些結構性優勢將在整個預測期內鞏固北美的主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療基礎設施現代化進程的快速推進、中產階級的壯大以及慢性病患病率的上升。中國、印度和韓國等國家正崛起為生物相似藥研發的主要中心，憑藉其低廉的生產成本和熟練的勞動力，在全球市場佔據了相當大的佔有率。政府為提升國內生物製藥能力和簡化核准流程所做的努力，正在加速市場成長。專利到期本土製造商提供了推出價格更親民的替代藥物的機會，從而顯著擴大了該地區龐大人口的患者用藥範圍。隨著醫療保健支出的持續成長，亞太地區正成為生物製藥領域成長最快的市場。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球生物製藥市場：依產品類型分類

  • 單株抗體
  • 重組蛋白
  • 疫苗
  • 細胞和基因治療
  • 治療酵素
  • 血液因子和凝血因子
  • 細胞激素和干擾素
  • 其他產品類型

第6章 全球生物製藥市場：依藥物分類

  • 原始生物製藥
  • 生物相似藥

第7章 全球生物製藥市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 其他路線

第8章 全球生物製藥市場：依生產模式分類

  • 內部生產
  • 契約製造（CMO/CDMO）

第9章 全球生物製藥市場：依治療應用分類

  • 腫瘤學
  • 自體免疫疾病
  • 感染疾病
  • 心血管疾病
  • 神經系統疾病
  • 代謝性疾病
  • 呼吸系統疾病
  • 其他治療用途

第10章 全球生物製藥市場：依最終用戶分類

  • 醫院和診所
  • 研究和學術機構
  • 居家醫療環境

第11章 全球生物製藥市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Pfizer Inc.
  • Roche Holding AG
  • Novartis AG
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Sanofi SA
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Limited
  • Biogen Inc.
  • Regeneron Pharmaceuticals Inc.
  • Gilead Sciences Inc.
Product Code: SMRC35962

According to Stratistics MRC, the Global Biopharmaceuticals Market is accounted for $607.0 billion in 2026 and is expected to reach $1330.0 billion by 2034 growing at a CAGR of 10.3% during the forecast period. Biopharmaceuticals are medical drugs produced using biotechnology methods, including therapeutic proteins, monoclonal antibodies, vaccines, and gene therapies derived from living organisms. These advanced treatments have revolutionized healthcare by targeting specific disease mechanisms with unprecedented precision, particularly in oncology, autoimmune disorders, and rare genetic diseases. The market encompasses both innovator biologics protected by patents and biosimilars that offer more affordable alternatives after patent expiration, creating a dynamic landscape of innovation, accessibility, and regulatory oversight across global healthcare systems.

Market Dynamics:

Driver:

Rising prevalence of chronic and autoimmune diseases

The global increase in conditions such as cancer, rheumatoid arthritis, diabetes, and multiple sclerosis is driving unprecedented demand for biopharmaceutical solutions. Unlike traditional small-molecule drugs, biologics offer targeted mechanisms that address underlying disease pathways, often providing effective treatment where conventional therapies fail. Aging populations in developed nations and lifestyle-related disease burdens in emerging economies further amplify this demand. Healthcare systems are increasingly prioritizing biologic treatments for chronic disease management, recognizing their potential to improve patient outcomes and reduce long-term hospitalization costs. This sustained clinical need creates a robust foundation for continued market expansion across all therapeutic categories.

Restraint:

High manufacturing and development costs

The complex nature of biologic drug production imposes substantial financial barriers that limit market accessibility and constrain innovation. Unlike chemically synthesized drugs, biopharmaceuticals require living cell cultures, stringent sterile conditions, and sophisticated purification processes, with manufacturing facilities costing hundreds of millions of dollars to construct and validate. Development timelines extending beyond a decade, combined with expensive clinical trials, mean that bringing a single biologic to market can exceed two billion dollars. These costs translate into high treatment prices, straining healthcare budgets and limiting patient access, particularly in developing economies where insurance coverage for expensive biologics remains inadequate.

Opportunity:

Expanding biosimilars market following patent expiries

The expiration of patents for blockbuster biologics is creating unprecedented opportunities for biosimilar development and market entry. Unlike generic drugs, biosimilars require extensive analytical and clinical testing to demonstrate similarity to reference products, yet they offer cost reductions of twenty to thirty percent, dramatically improving patient access. Major biologic patents for drugs treating autoimmune diseases, cancer, and diabetes are expiring throughout the forecast period, opening multi-billion dollar markets for biosimilar manufacturers. Regulatory pathways in the United States, Europe, and emerging markets have matured, providing clearer approval frameworks. This wave of biosimilar launches is expected to transform treatment landscapes while creating substantial revenue opportunities for developers.

Threat:

Immunogenicity and safety concerns

The biological nature of these therapeutics introduces risks of unwanted immune responses that threaten patient safety and regulatory approval. Immunogenicity, where the patient's immune system recognizes the biologic as foreign and produces anti-drug antibodies, can neutralize therapeutic effects, alter pharmacokinetics, or trigger severe allergic reactions including anaphylaxis. Even minor manufacturing changes can alter product immunogenicity profiles, requiring extensive post-approval monitoring. High-profile safety incidents have led to product withdrawals and intensified regulatory scrutiny, increasing development uncertainty. These concerns create particular challenges for biosimilars, where even subtle differences from reference products may provoke unexpected immune reactions, potentially limiting physician and patient acceptance.

Covid-19 Impact:

The COVID-19 pandemic had a complex impact on the biopharmaceuticals market, both disrupting and accelerating different segments. Lockdowns and healthcare reallocation delayed clinical trials for non-COVID biologic candidates, while also causing supply chain interruptions for raw materials. However, the pandemic dramatically accelerated vaccine development platforms, with mRNA technology achieving regulatory approval in record time, validating novel biopharmaceutical approaches. Increased hospitalizations overwhelmed healthcare systems, temporarily reducing elective biologic treatment initiations for chronic conditions. The pandemic also highlighted the strategic importance of domestic biomanufacturing capacity, prompting government investments and policy changes that will benefit the broader biopharmaceutical industry in the long term.

The Innovator Biologics segment is expected to be the largest during the forecast period

The Innovator Biologics segment is expected to account for the largest market share during the forecast period, driven by robust patent protections and the continuous pipeline of novel biologic entities. Pharmaceutical companies invest heavily in research and development to discover first-in-class monoclonal antibodies, fusion proteins, and gene therapies that address unmet medical needs. These innovator products command premium pricing and market exclusivity periods of up to twelve years following regulatory approval. The oncology segment alone has witnessed numerous blockbuster innovator biologics achieving annual sales exceeding five billion dollars. Strong intellectual property regimes and regulatory incentives for orphan drug development ensure that innovator biologics maintain market dominance throughout the forecast period.

The Oral segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Oral segment is predicted to witness the highest growth rate, reflecting significant technological breakthroughs in delivering biologic drugs through non-injectable routes. Traditional biopharmaceuticals require injection due to degradation in the gastrointestinal tract, but novel formulation technologies including permeation enhancers, enzyme inhibitors, and advanced encapsulation are enabling oral delivery of peptides and small proteins. Patient preference strongly favors oral administration over injectables, improving treatment adherence for chronic conditions requiring long-term therapy. Several oral peptide formulations for conditions including diabetes and rheumatoid arthritis have recently received regulatory approval, with many more in late-stage development. This transformative shift promises to dramatically expand biologic accessibility and convenience.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, underpinned by a mature biotechnology ecosystem, substantial research funding, and favorable reimbursement policies. The United States alone accounts for nearly half of global biopharmaceutical research and development spending, hosting the headquarters of most major innovator companies. The region's regulatory framework, including the Biologics Price Competition and Innovation Act, provides clear pathways for both innovator and biosimilar approvals. Strong intellectual property protection encourages continuous investment, while widespread private and public insurance coverage ensures patient access to expensive biologic therapies. These structural advantages cement North America's leadership position throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by rapidly modernizing healthcare infrastructure, growing middle-class populations, and increasing prevalence of chronic diseases. Countries including China, India, and South Korea have emerged as major hubs for biosimilar development, leveraging lower manufacturing costs and skilled workforces to capture significant global market share. Government initiatives promoting domestic biomanufacturing capabilities and streamlining approval processes accelerate market growth. The expiration of biologic patents creates opportunities for local manufacturers to introduce affordable alternatives, dramatically expanding patient access across the region's large populations. As healthcare spending continues to rise, Asia Pacific emerges as the fastest-growing market for biopharmaceuticals.

Key players in the market

Some of the key players in Biopharmaceuticals Market include Pfizer Inc., Roche Holding AG, Novartis AG, Johnson & Johnson, Merck & Co. Inc., Sanofi SA, GlaxoSmithKline plc, AstraZeneca plc, AbbVie Inc., Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Regeneron Pharmaceuticals Inc. and Gilead Sciences Inc.

Key Developments:

In April 2026, AbbVie showcased late-breaking Phase 2 data for Mirvetuximab Soravtansine-gynx (ELAHERE) in platinum-sensitive ovarian cancer, indicating a potential shift in the standard of care.

In December 2025, Novartis received a positive CHMP opinion for Scemblix across all lines of CML treatment, expanding its oncology footprint in Europe.

In December 2025, Pfizer completed a $10.4 billion internal R&D reinvestment cycle for 2025 and finalized $8.8 billion business development expenditure, primarily focused on the Metsera acquisition and a new 3SBio in-licensing deal to bolster its metabolic pipeline.

Product Types Covered:

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Cell and Gene Therapies
  • Therapeutic Enzymes
  • Blood Factors and Coagulation Factors
  • Cytokines and Interferons
  • Other Product Types

Drug Classifications Covered:

  • Innovator Biologics
  • Biosimilars

Route of Administrations Covered:

  • Injectable
  • Oral
  • Other Routes

Manufacturing Models Covered:

  • In-house Manufacturing
  • Outsourced Manufacturing (CMOs/CDMOs)

Therapeutic Applications Covered:

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Metabolic Disorders
  • Respiratory Diseases
  • Other Therapeutic Applications

End Users Covered:

  • Hospitals and Clinics
  • Research and Academic Institutes
  • Homecare Settings

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Biopharmaceuticals Market, By Product Type

  • 5.1 Monoclonal Antibodies
  • 5.2 Recombinant Proteins
  • 5.3 Vaccines
  • 5.4 Cell and Gene Therapies
  • 5.5 Therapeutic Enzymes
  • 5.6 Blood Factors and Coagulation Factors
  • 5.7 Cytokines and Interferons
  • 5.8 Other Product Types

6 Global Biopharmaceuticals Market, By Drug Classification

  • 6.1 Innovator Biologics
  • 6.2 Biosimilars

7 Global Biopharmaceuticals Market, By Route of Administration

  • 7.1 Injectable
  • 7.2 Oral
  • 7.3 Other Routes

8 Global Biopharmaceuticals Market, By Manufacturing Model

  • 8.1 In-house Manufacturing
  • 8.2 Outsourced Manufacturing (CMOs/CDMOs)

9 Global Biopharmaceuticals Market, By Therapeutic Application

  • 9.1 Oncology
  • 9.2 Autoimmune Diseases
  • 9.3 Infectious Diseases
  • 9.4 Cardiovascular Diseases
  • 9.5 Neurological Disorders
  • 9.6 Metabolic Disorders
  • 9.7 Respiratory Diseases
  • 9.8 Other Therapeutic Applications

10 Global Biopharmaceuticals Market, By End User

  • 10.1 Hospitals and Clinics
  • 10.2 Research and Academic Institutes
  • 10.3 Homecare Settings

11 Global Biopharmaceuticals Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Pfizer Inc.
  • 14.2 Roche Holding AG
  • 14.3 Novartis AG
  • 14.4 Johnson & Johnson
  • 14.5 Merck & Co. Inc.
  • 14.6 Sanofi SA
  • 14.7 GlaxoSmithKline plc
  • 14.8 AstraZeneca plc
  • 14.9 AbbVie Inc.
  • 14.10 Amgen Inc.
  • 14.11 Bristol Myers Squibb Company
  • 14.12 Eli Lilly and Company
  • 14.13 Takeda Pharmaceutical Company Limited
  • 14.14 Biogen Inc.
  • 14.15 Regeneron Pharmaceuticals Inc.
  • 14.16 Gilead Sciences Inc.

List of Tables

  • Table 1 Global Biopharmaceuticals Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Biopharmaceuticals Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 3 Global Biopharmaceuticals Market Outlook, By Monoclonal Antibodies (2023-2034) ($MN)
  • Table 4 Global Biopharmaceuticals Market Outlook, By Recombinant Proteins (2023-2034) ($MN)
  • Table 5 Global Biopharmaceuticals Market Outlook, By Vaccines (2023-2034) ($MN)
  • Table 6 Global Biopharmaceuticals Market Outlook, By Cell and Gene Therapies (2023-2034) ($MN)
  • Table 7 Global Biopharmaceuticals Market Outlook, By Therapeutic Enzymes (2023-2034) ($MN)
  • Table 8 Global Biopharmaceuticals Market Outlook, By Blood Factors and Coagulation Factors (2023-2034) ($MN)
  • Table 9 Global Biopharmaceuticals Market Outlook, By Cytokines and Interferons (2023-2034) ($MN)
  • Table 10 Global Biopharmaceuticals Market Outlook, By Other Product Types (2023-2034) ($MN)
  • Table 11 Global Biopharmaceuticals Market Outlook, By Drug Classification (2023-2034) ($MN)
  • Table 12 Global Biopharmaceuticals Market Outlook, By Innovator Biologics (2023-2034) ($MN)
  • Table 13 Global Biopharmaceuticals Market Outlook, By Biosimilars (2023-2034) ($MN)
  • Table 14 Global Biopharmaceuticals Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 15 Global Biopharmaceuticals Market Outlook, By Injectable (2023-2034) ($MN)
  • Table 16 Global Biopharmaceuticals Market Outlook, By Oral (2023-2034) ($MN)
  • Table 17 Global Biopharmaceuticals Market Outlook, By Other Routes (2023-2034) ($MN)
  • Table 18 Global Biopharmaceuticals Market Outlook, By Manufacturing Model (2023-2034) ($MN)
  • Table 19 Global Biopharmaceuticals Market Outlook, By In-house Manufacturing (2023-2034) ($MN)
  • Table 20 Global Biopharmaceuticals Market Outlook, By Outsourced Manufacturing (CMOs/CDMOs) (2023-2034) ($MN)
  • Table 21 Global Biopharmaceuticals Market Outlook, By Therapeutic Application (2023-2034) ($MN)
  • Table 22 Global Biopharmaceuticals Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 23 Global Biopharmaceuticals Market Outlook, By Autoimmune Diseases (2023-2034) ($MN)
  • Table 24 Global Biopharmaceuticals Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 25 Global Biopharmaceuticals Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 26 Global Biopharmaceuticals Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 27 Global Biopharmaceuticals Market Outlook, By Metabolic Disorders (2023-2034) ($MN)
  • Table 28 Global Biopharmaceuticals Market Outlook, By Respiratory Diseases (2023-2034) ($MN)
  • Table 29 Global Biopharmaceuticals Market Outlook, By Other Therapeutic Applications (2023-2034) ($MN)
  • Table 30 Global Biopharmaceuticals Market Outlook, By End User (2023-2034) ($MN)
  • Table 31 Global Biopharmaceuticals Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 32 Global Biopharmaceuticals Market Outlook, By Research and Academic Institutes (2023-2034) ($MN)
  • Table 33 Global Biopharmaceuticals Market Outlook, By Homecare Settings (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.